Fortress Biotech Inc (FBIO)-Pharmaceuticals & Healthcare-Deals and Alliances Profile

Fortress Biotech Inc (FBIO)-Pharmaceuticals & Healthcare-Deals and Alliances Profile


  • Products Id :- GDPH135290D
  • |
  • Pages: 89
  • |
  • |
  • |
  Request for Sample Report
  Request A Quote

Executive Summary

Summary

Fortress Biotech Inc (Fortress), formerly Coronado Biosciences Inc is a biopharmaceutical company that develops and commercializes pharmaceutical and biotechnology products. The company offers products in the areas of dermatology, cancer, pain management and autoimmune diseases, among others. It offers Dermasorb HC, Luxamed wound cream and Ceracade. Fortress's products are used to treat and manage atopic dermatitis, wounds and other dermatological diseases. The company also provides funding to support their research and development programs. It markets its products in the US and abroad. Fortress is headquartered in New York, the US.

Fortress Biotech Inc (FBIO)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

Business Description-A brief description of the company's operations.

Key Employees-A list of the key executives of the company.

Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

Key Competitors-A list of the key competitors of the company.

Key Recent Developments-A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.



Read More



Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications

+91-9015378249

Table of Contents

Table of Contents

List of Tables

List of Figures

Fortress Biotech Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018

Fortress Biotech Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018

Fortress Biotech Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018

Fortress Biotech Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018

Fortress Biotech Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018

Fortress Biotech Inc, Pharmaceuticals & Healthcare, Deal Details

Asset Purchase

Altamira Bio Acquires NIH License and CRADAs Relating to the Development of ManNAc from New Zealand Pharma

Venture Financing

Avenue Therapeutics Raises USD0.2 Million in Venture Financing

Helocyte Raises Additional USD2 Million in Venture Financing

Helocyte Raises USD1 Million in Venture Financing

Checkpoint Therapeutics Raises USD57.8 Million Venture Financing

Partnerships

Aevitas Therapeutics Enters into Research Agreement with University of Massachusetts Medical School

Mustang Bio Enters into Agreement with Beth Israel Deaconess

Cyprium Therapeutics Enters into Research and Development Agreement with Eunice Kennedy Shriver NICHD

Helocyte Enters into Agreement with City of Hope for PepVax

Helocyte Enters into Agreement with City of Hope

Checkpoint Therapeutics Enters into Research Agreement with NeuPharma

Coronado Biosciences Forms Joint Venture with City of Hope

TG Therapeutics Extends its Option Agreement with Checkpoint Therapeutics

TG Therapeutics Enters into Agreement with Checkpoint Therapeutics to Develop and Commercialize Immuno-Oncology Targeted Antibodies

Licensing Agreements

Mustang Bio Enters into Licensing Agreement with Harvard University

Mustang Bio Enters into Licensing Agreement with Fred Hutchinson Cancer Research Center

Mustang Bio Enters into Licensing Agreement with City of Hope

NICHD Enters into Licensing Agreement with Cyprium Therapeutics

Fortress Biotech Enters into Licensing Agreement with Columbia University

Cellvation Enters into Licensing Agreement with University of Texas Health Science Center at Houston

Fortress Biotech Enters into Licensing Agreement with Effcon Labs

Fortress Biotech Enters into Licensing Agreement with GeneMedicine

Checkpoint Therapeutics Amends its Licensing Agreement with Jubilant Biosys

Journey Medical Enters into Licensing Agreement for Ceracade

Journey Medical Enters into Licensing Agreement for Luxamend

Checkpoint Therapeutics Enters into Licensing Agreement with Cephalon

Helocyte Exercises Option for Licensing Agreement with City of Hope for Pentamer

Mustang Bio Enters into Licensing Agreement with City of Hope

Helocyte Amends Agreement with City of Hope National Medical Center

Journey Medical Enters into Licensing Agreement for Dermatological Product

Fortress Biotech Amends its Licensing Agreement with NeuPharma

Checkpoint Therapeutics Amends its Licensing Agreement with Dana-Farber Cancer Institute

Coronado Enters Into Licensing Agreement for Product to Treat Hand-Foot Syndrome

Coronado Biosciences Enters into Licensing Agreement with Revogenex Ireland for IV Tramadol

Coronado Biosciences Enters Into Licensing Agreement With Freie Universitat Berlin For Secretory Products Of Trichuris Suis

Coronado Biosciences Enters Into Licensing Agreement With Dr. Falk Pharma For Europe Application

Coronado Biosciences Expands Licensing Agreement With Ovamed For Manufacturing Rights Of TSO

Dr. Falk Pharma Enters Into Licensing Agreement With Coronado Biosciences For CNDO-201

Equity Offering

Checkpoint Therapeutics Plans to Raise up to USD100 Million in Public Offering of Shares

Fortress Biotech Prices Public Offering of Series A Preferred Shares for USD25 million

Avenue Therapeutics Raises USD38 Million in IPO

Checkpoint Therapeutics Plans to Raise up to USD50 Million in Public Offering of Shares

Mustang Bio Raises USD7.1 Million in Second Tranche of Private Placement of Units

Mustang Bio Raises USD12.4 Million in First Tranche of Private Placement of Units

Checkpoint Therapeutics Raises USD0.6 Million in Private Placement of Units

Checkpoint Therapeutics Raises USD58 Million in Private Placement of Units

Coronado Biosciences Raises USD3.5 Million in Private Placement of Shares

Coronado Biosciences Files Registration Statement For Public Offering Of Securities For USD200 Million

Coronado Biosciences Announces Public Offering Of Common Stock For USD45 Million

Coronado Biosciences Completes Third Tranche Of Public Offering Of Common Stock For USD10 Million

Coronado Biosciences Completes Public Offering Of Shares For USD28.8 Million

Debt Offering

Fortress Biotech Raises USD3.3 Million in Private Placement of 8% Notes Due 2020

Fortress Biotech Inc-Key Competitors

Fortress Biotech Inc-Key Employees

Fortress Biotech Inc-Locations And Subsidiaries

Head Office

Other Locations & Subsidiaries

Joint Venture

Recent Developments

Financial Announcements

Nov 09, 2017: Fortress Biotech Reports Third Quarter 2017 Financial Results and Recent Corporate Highlights

Aug 14, 2017: Mustang Bio Reports Second Quarter 2017 Financial Results and Recent Corporate Highlights

Aug 09, 2017: Fortress Biotech Reports Second Quarter 2017 Financial Results and Recent Corporate Highlights

May 10, 2017: Fortress Biotech Reports First Quarter 2017 Financial Results and Recent Corporate Highlights

Mar 16, 2017: Fortress Biotech Reports Financial Results for the Fourth Quarter and Full Year Ended December 31, 2016

Corporate Communications

Jul 03, 2017: Fortress Biotech Announces Appointment of Lucy Lu, MD, as President and Chief Executive Officer of Subsidiary Avenue Therapeutics

Jul 03, 2017: Fortress Biotech names president and CEO of Avenue Therapeutics

Mar 14, 2017: Fortress Biotech Announces Appointment of Lung S. Yam, M.D., Ph.D., Named Cyprium Chief Executive Officer

Jan 04, 2017: Fortress Biotech announce the appointment of Michael Spector as Caelum's Chief Executive Officer.

Appendix

Methodology

About GlobalData

Contact Us

Disclaimer

List of Figures

Fortress Biotech Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018

Fortress Biotech Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018

Fortress Biotech Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018

Fortress Biotech Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018

Fortress Biotech Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018

Fortress Biotech Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018

Fortress Biotech Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018

Fortress Biotech Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018

List of Tables

Fortress Biotech Inc, Pharmaceuticals & Healthcare, Key Facts, 2016

Fortress Biotech Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018

Fortress Biotech Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018

Fortress Biotech Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018

Fortress Biotech Inc, Deals By Therapy Area, 2012 to YTD 2018

Fortress Biotech Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018

Altamira Bio Acquires NIH License and CRADAs Relating to the Development of ManNAc from New Zealand Pharma

Avenue Therapeutics Raises USD0.2 Million in Venture Financing

Helocyte Raises Additional USD2 Million in Venture Financing

Helocyte Raises USD1 Million in Venture Financing

Checkpoint Therapeutics Raises USD57.8 Million Venture Financing

Aevitas Therapeutics Enters into Research Agreement with University of Massachusetts Medical School

Mustang Bio Enters into Agreement with Beth Israel Deaconess

Cyprium Therapeutics Enters into Research and Development Agreement with Eunice Kennedy Shriver NICHD

Helocyte Enters into Agreement with City of Hope for PepVax

Helocyte Enters into Agreement with City of Hope

Checkpoint Therapeutics Enters into Research Agreement with NeuPharma

Coronado Biosciences Forms Joint Venture with City of Hope

TG Therapeutics Extends its Option Agreement with Checkpoint Therapeutics

TG Therapeutics Enters into Agreement with Checkpoint Therapeutics to Develop and Commercialize Immuno-Oncology Targeted Antibodies

Mustang Bio Enters into Licensing Agreement with Harvard University

Mustang Bio Enters into Licensing Agreement with Fred Hutchinson Cancer Research Center

Mustang Bio Enters into Licensing Agreement with City of Hope

NICHD Enters into Licensing Agreement with Cyprium Therapeutics

Fortress Biotech Enters into Licensing Agreement with Columbia University

Cellvation Enters into Licensing Agreement with University of Texas Health Science Center at Houston

Fortress Biotech Enters into Licensing Agreement with Effcon Labs

Fortress Biotech Enters into Licensing Agreement with GeneMedicine

Checkpoint Therapeutics Amends its Licensing Agreement with Jubilant Biosys

Journey Medical Enters into Licensing Agreement for Ceracade

Journey Medical Enters into Licensing Agreement for Luxamend

Checkpoint Therapeutics Enters into Licensing Agreement with Cephalon

Helocyte Exercises Option for Licensing Agreement with City of Hope for Pentamer

Mustang Bio Enters into Licensing Agreement with City of Hope

Helocyte Amends Agreement with City of Hope National Medical Center

Journey Medical Enters into Licensing Agreement for Dermatological Product

Fortress Biotech Amends its Licensing Agreement with NeuPharma

Checkpoint Therapeutics Amends its Licensing Agreement with Dana-Farber Cancer Institute

Coronado Enters Into Licensing Agreement for Product to Treat Hand-Foot Syndrome

Coronado Biosciences Enters into Licensing Agreement with Revogenex Ireland for IV Tramadol

Coronado Biosciences Enters Into Licensing Agreement With Freie Universitat Berlin For Secretory Products Of Trichuris Suis

Coronado Biosciences Enters Into Licensing Agreement With Dr. Falk Pharma For Europe Application

Coronado Biosciences Expands Licensing Agreement With Ovamed For Manufacturing Rights Of TSO

Dr. Falk Pharma Enters Into Licensing Agreement With Coronado Biosciences For CNDO-201

Checkpoint Therapeutics Plans to Raise up to USD100 Million in Public Offering of Shares

Fortress Biotech Prices Public Offering of Series A Preferred Shares for USD25 million

Avenue Therapeutics Raises USD38 Million in IPO

Checkpoint Therapeutics Plans to Raise up to USD50 Million in Public Offering of Shares

Mustang Bio Raises USD7.1 Million in Second Tranche of Private Placement of Units

Mustang Bio Raises USD12.4 Million in First Tranche of Private Placement of Units

Checkpoint Therapeutics Raises USD0.6 Million in Private Placement of Units

Checkpoint Therapeutics Raises USD58 Million in Private Placement of Units

Coronado Biosciences Raises USD3.5 Million in Private Placement of Shares

Coronado Biosciences Files Registration Statement For Public Offering Of Securities For USD200 Million

Coronado Biosciences Announces Public Offering Of Common Stock For USD45 Million

Coronado Biosciences Completes Third Tranche Of Public Offering Of Common Stock For USD10 Million

Coronado Biosciences Completes Public Offering Of Shares For USD28.8 Million

Fortress Biotech Raises USD3.3 Million in Private Placement of 8% Notes Due 2020

Fortress Biotech Inc, Key Competitors

Fortress Biotech Inc, Key Employees

Fortress Biotech Inc, Other Locations

Fortress Biotech Inc, Subsidiaries

Fortress Biotech Inc, Joint Venture

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to sales [@] kenresearch.com
 

select a license

Single User License
USD 250 INR 16863
Site License
USD 500 INR 33725
Corporate User License
USD 750 INR 50588

NEWSLETTER BY CATEGORY




Testimonials

An excellent provider. Thorough, precise and outstanding insight. They drill down to what we need and their reports are effective at integrating text with supporting graphics and charts. Their reports are a great resource to go back too. ...

Coherent, high-quality, thoroughly-researched reports. We received a very quick response to all our queries which eventually expedited the entire process....

Well structured, the insights they shared with us were very helpful and reliable. Their timely assistance make their services invaluable to us. I would highly recommend them and would definitely use them again in the future if needed...

The report sent to us was on the point, and its information was quite extensive, well structured, and well researched. More importantly what we valued was your response time and professionalism. As a leading global consulting firm, our clients expect high quality deliverables in short periods of time, so a reliable research partner is essential. For the price that you have charged the quality of your services were exceptional. We look forward to continue our relationship with your team on future engagements....

This is with regards to your report on India PVC pipes and fitting market outlook industry outlook to 2019. This is a very well written report and accept my compliments on the same.... ...



Ken Research Pvt. Ltd. Unit 14, Tower B3, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India

download

Company Brochure

Engage with Us

sales [@] kenresearch.com